Prevalence of atrial fibrillation and eligibility for anticoagulants in the community.
about
Electrical cardioversion for atrial fibrillation and flutterPharmacological cardioversion for atrial fibrillation and flutterCollaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsA randomised controlled trial and cost effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in the over 65s: (SAFE) [ISRCTN19633732]Occurrence and quality of anticoagulant treatment of chronic atrial fibrillation in primary health care in Sweden: a retrospective study on electronic patient recordsProtocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN893A randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation: the DAAFI trial protocol [ISRCTN14429643]Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A ReviewTrends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research databaseImportance of risk communication and decision making in cardiovascular conditions in older patients: a discussion paperA patient decision aid to support shared decision-making on anti-thrombotic treatment of patients with atrial fibrillation: randomised controlled trialA community-based educational intervention to improve antithrombotic drug use in atrial fibrillationA cautionary note on data sources for evidence-based clinical decisions: warfarin and stroke preventionA national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in ScotlandImplementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after studyComorbidity associated with atrial fibrillation: a general practice-based studyEffects of patients' preferences on the treatment of atrial fibrillation: observational study of patient-based decision analysis.Is warfarin really underused in patients with atrial fibrillation?Anticoagulation for patients with atrial fibrillation. Editorial may have overinterpreted data.Value of pacemaker atrial diagnostic data in patients with paroxysmal atrial fibrillation: an opportunity to improve rates of warfarin utilization.Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial.Rapid access arrhythmia clinic for the diagnosis and management of new arrhythmias presenting in the community: a prospective, descriptive study.Catheter ablation in combination with left atrial appendage closure for atrial fibrillation.Quality of anticoagulation and use of warfarin-interacting medications in long-term care: a chart review.Antithrombotic therapy in nonrheumatic/nonvalvular atrial fibrillation.Using anticoagulation or aspirin to prevent stroke. Research was methodologically flawed.Percutaneous elimination of the left atrial appendage in quest for effective and safe prevention of stroke in patients with atrial fibrillation.A community survey of patients with atrial fibrillation: associated disabilities and treatment preferences.Could some geriatric characteristics hinder the prescription of anticoagulants in atrial fibrillation in the elderly?Cardiac imaging for assessment of left atrial appendage stasis and thrombosis.A comprehensive view of sex-specific issues related to cardiovascular disease.Risk factors of stroke in Western and Asian countries: a systematic review and meta-analysis of prospective cohort studies.Stroke risk in an elderly population with atrial fibrillation.Atrial fibrillation in the elderly: anticoagulation strategies and indications in the very elderly.Impact of atrial fibrillation on healthcare utilization in the community: the Atherosclerosis Risk in Communities study.Clinical pharmacology and therapeutics into the future.Antioxidant vitamins in the prevention of atrial fibrillation: what is the evidence?The clinical pharmacology of ageing.An audit of the role of vitamin K in the reversal of International Normalised Ratio (INR) in patients undergoing surgery for hip fracture.Management of warfarin anticoagulation in patients with fractured neck of femur.
P2860
Q24246610-B4D300BA-B304-4E0B-982B-31D22283700EQ24246997-CE7CE861-E436-4E84-BF45-F8344194104AQ24555072-5D2698C9-6754-46A6-9A8B-C3A8AAE5106CQ24798085-690283F0-3446-482C-ADC7-903FC03E2AC7Q24800847-93B9B8FB-C497-4F59-8473-9C8ECC42D0ADQ24801915-9D281A46-E13F-41A7-AEA0-D9B109B364D7Q24803243-ECFAFC05-D828-44AB-B5A3-AC09E947F3CFQ26765949-94683A0E-D91E-4980-8798-9A4F0B7C8F3BQ28188181-48C813F9-1AF4-4B95-816C-29FD34F6CFCCQ28188630-E1288B67-5829-48D5-A1DE-64FE591F90ADQ28212218-D89E6AF0-CB52-4C36-B67D-9119433DC243Q28213965-B1E39C9D-431C-404E-B0DA-442D4C126651Q28218659-5C3CA1E8-70BC-4AE5-B2A9-7E0A8590D940Q28218708-FD17CD7F-789F-4A0A-8C45-1DAA0A256B7EQ28219345-EC8C6B18-B83F-438A-A3CF-6D3F14D08A6EQ28344172-84BB0BAA-6205-4886-9FBD-60DB87BAE611Q28364493-F04761B1-CBDE-4138-BB48-C4969A38F799Q28365245-24BA0980-643E-4390-A9CF-8E0EE6CB2F39Q30616220-F4767940-F309-4F77-9C9A-757930811734Q31109552-C9CDCB8B-1E6C-473E-8DBB-996B5A4133C9Q31117354-3C0D4310-F016-4D11-9939-C4544E17251CQ33151588-ED7AE8D5-45F6-4D75-A686-5F3D71677CE4Q33162506-D183E9A1-686F-48ED-909A-CC09CD89634BQ33348847-B8EC6531-9F18-4EFF-B49B-129052B0C685Q33598010-32D6F733-2441-4B32-B06D-037654FA2418Q33800650-60447FF5-974A-4B7F-9ECA-6508923350C8Q33941300-3E460ED4-0439-4EE0-83F9-3BA836276FC7Q34216056-4B6A9579-8939-4AC0-972E-A42722E9A88FQ34245296-B6D47B8A-2FED-4EA8-A54D-9761FAD8C321Q34423822-A957110E-2E4E-4E9A-AE16-26E29B55AD6EQ34577461-5DB26307-BE42-4D81-AD05-E17C195CCBB7Q34581666-622932BB-225C-4165-9DF9-633E36C0316BQ34749458-919EED5E-87FC-408B-8151-6124F594D814Q34989728-ADA3CB94-6261-4451-81E4-1BF84C7676FCQ35114854-C4587BEC-1B37-4795-98A1-97CBD8196E47Q35130827-228C7B9F-7777-46D4-B594-A7E7E97CC8FDQ35184349-C8818A75-9951-4EF1-9C0F-780B241A8CA4Q35200040-AAD0C080-D58E-4B6A-83E0-4BECF35FC064Q35240241-730AC82A-80AD-4BEB-AF4B-AAE78FD567DDQ35368699-4202DFD9-D382-4E27-B729-86AEE9BF747A
P2860
Prevalence of atrial fibrillation and eligibility for anticoagulants in the community.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Prevalence of atrial fibrillation and eligibility for anticoagulants in the community.
@en
Prevalence of atrial fibrillation and eligibility for anticoagulants in the community.
@nl
type
label
Prevalence of atrial fibrillation and eligibility for anticoagulants in the community.
@en
Prevalence of atrial fibrillation and eligibility for anticoagulants in the community.
@nl
prefLabel
Prevalence of atrial fibrillation and eligibility for anticoagulants in the community.
@en
Prevalence of atrial fibrillation and eligibility for anticoagulants in the community.
@nl
P2093
P1433
P1476
Prevalence of atrial fibrillation and eligibility for anticoagulants in the community.
@en
P2093
P304
P356
10.1016/S0140-6736(98)01401-9
P407
P577
1998-10-01T00:00:00Z